Evolution of Cefiderocol Non-Susceptibility inPseudomonas aeruginosain a Patient Without Previous Exposure to the Antibiotic | Zendy

Ana Paula Streling | Zendy; Mohanad M. Al Obaidi | Zendy; William Lainhart | Zendy; Tirdad T. Zangeneh | Zendy; Ayesha Khan | Zendy; An Q Dinh | Zendy; Blake Hanson | Zendy; César A. Arias | Zendy; William R. Miller | Zendy

Open Access

Evolution of Cefiderocol Non-Susceptibility inPseudomonas aeruginosain a Patient Without Previous Exposure to the Antibiotic

Author(s) -

Ana Paula Streling,

Mohanad M. Al Obaidi,

William Lainhart,

Tirdad T. Zangeneh,

Ayesha Khan,

An Q Dinh,

Blake Hanson,

César A. Arias,

William R. Miller

Publication year - 2021

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciaa1909

Subject(s) - pseudomonas aeruginosa , medicine , antibiotics , microbiology and biotechnology , bacteria , biology , genetics

We report the emergence of non-susceptibility to cefiderocol from a subpopulation of Pseudomonas aeruginosa recovered from a patient without history of cefiderocol exposure. Whole genome sequencing identified mutations in major iron transport pathways previously associated with cefiderocol uptake. Susceptibility testing should be performed before therapy with siderophore cephalosporins.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research